Tumor Board Continues to Grow with New Members to Advance Breakthrough Treatments for Synovial Sarcoma Patients
The National Synovial Sarcoma Tumor Board, a dedicated multidisciplinary team committed to improving outcomes for individuals affected by synovial sarcoma, is pleased to announce the ongoing expansion of its membership. This growth reflects our steadfast dedication to fostering innovative treatment strategies and providing personalized care for more patients nationwide.
We are proud to share that the Tumor Board now includes 42 participating institutions, strengthening our collective expertise and reach. Recent additions include Duke Health in North Carolina, Johns Hopkins University in Maryland, and the University of Minnesota/Masonic Cancer Center in Minnesota. These new members, along with our existing institutions, greatly enhance our ability to develop and implement cutting-edge, individualized treatment plans.
“Our goal is to push the boundaries of current treatment approaches and offer hope to patients facing this challenging diagnosis,” said Nathan Imperiale, Chairman of the Synovial Sarcoma Foundation. “The new medical professionals bring valuable insights and experience, which will help us refine our strategies and reach more patients who can benefit from innovative therapies.”
The Tumor Board’s continued growth underscores the foundation’s commitment to leading advancements in synovial sarcoma treatment and ensuring that every patient receives expert, tailored care. If your doctor or care team is not currently participating, please share this information with them! The Synovial Sarcoma Tumor Board offers an incredible opportunity for medical professionals to collaborate with leading experts and provide the best possible care for their patients.
The current list of participating institutions includes:
- Atrium Health
- Augusta Oncology
- Barnes-Jewish Hospital
- CancerCare Manitoba
- Cedars-Sinai
- Children’s Hospital Colorado
- Children’s Hospital Los Angeles
- Children’s Hospital Medical Center of Akron
- Children’s Hospital of Orange County
- Children’s Hospital of Philadelphia
- Cincinnati Children’s Hospital
- City of Hope
- Cleveland Clinic
- Columbia
- Dana-Farber/Harvard Cancer Center
- Dell Children’s Medical Center of Central Texas
- John Hopkins
- Kaiser Permanente Northern California
- Lucile Packard Children’s Hospital
- Maine Health
- Mayo AZ
- Mayo Clinic
- MD Anderson Cancer Center
- MD Anderson in Phoenix
- Memorial Sloan Kettering Cancer Center
- Nationwide Children’s Hospital
- Northwestern Medicine
- NYU Langhorne
- Penn Medicine
- Roswell Park Comprehensive Cancer Center
- Seattle Children’s Hospital
- St Jude Children’s Research Hospital
- Stanford
- UC Davis
- UC San Diego
- UC Santa Cruz
- UCLA Health
- UCSF Benioff Children’s Hospital
- University of Rochester
- University of Alabama at Birmingham
- University of Arkansas for Medical Sciences
- University of Colorado
- University of Miami
- University of Utah Health / Primary Children’s Hospital
- University of Washington
- UT Southwestern / Simmons Cancer Center-Dallas
- Valley Children’s Hospital
- Vanderbilt
For more information about the Tumor Board and how it is working to transform synovial sarcoma treatment, please visit our website.
